UY38994A - Compuestos activos frente a receptores nucleares - Google Patents

Compuestos activos frente a receptores nucleares

Info

Publication number
UY38994A
UY38994A UY0001038994A UY38994A UY38994A UY 38994 A UY38994 A UY 38994A UY 0001038994 A UY0001038994 A UY 0001038994A UY 38994 A UY38994 A UY 38994A UY 38994 A UY38994 A UY 38994A
Authority
UY
Uruguay
Prior art keywords
nuclear receptors
active compounds
compounds against
against nuclear
compounds
Prior art date
Application number
UY0001038994A
Other languages
English (en)
Inventor
Glad Sanne Schrøder
Thomas Franch
Alex Haahr Gouliaev
Søren Jensby Nielsen
Luigi Piero Stasi
SOLÀ Montserrat ERRA
Martínez Lorena Taboada
Moll Joan Taltavull
Javaloyes Juan Francisco Caturla
Santacana Lluís Miquel Pagès
Ian Sarvary
Original Assignee
Nuevolution As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuevolution As filed Critical Nuevolution As
Publication of UY38994A publication Critical patent/UY38994A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos activos frente a receptores nucleares, composiciones farmacéuticas que contienen los compuestos y el uso de los compuestos en terapia.
UY0001038994A 2019-12-20 2020-12-18 Compuestos activos frente a receptores nucleares UY38994A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951221P 2019-12-20 2019-12-20
US202063064502P 2020-08-12 2020-08-12

Publications (1)

Publication Number Publication Date
UY38994A true UY38994A (es) 2021-07-30

Family

ID=74003834

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038994A UY38994A (es) 2019-12-20 2020-12-18 Compuestos activos frente a receptores nucleares

Country Status (18)

Country Link
US (2) US11685727B2 (es)
EP (1) EP4076661A1 (es)
JP (2) JP2023506357A (es)
KR (1) KR20220118425A (es)
CN (1) CN114728170B (es)
AU (1) AU2020408107A1 (es)
BR (1) BR112022012205A2 (es)
CA (1) CA3160508A1 (es)
CL (1) CL2022001692A1 (es)
CO (1) CO2022009510A2 (es)
CR (1) CR20220355A (es)
IL (1) IL291774A (es)
JO (1) JOP20220160A1 (es)
MX (1) MX2022007391A (es)
PE (1) PE20230240A1 (es)
TW (1) TW202128661A (es)
UY (1) UY38994A (es)
WO (1) WO2021124279A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
MX2022012259A (es) 2020-03-31 2022-12-08 Nuevolution As Compuestos activos frente a receptores nucleares.
CN113461687B (zh) * 2021-08-10 2022-04-19 四川大学华西医院 2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途
CN116570589A (zh) * 2023-05-30 2023-08-11 南阳理工学院 化合物Parimifasor在制备抗肿瘤药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1756084T3 (da) * 2004-06-04 2009-03-23 Arena Pharm Inc Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
JP6624594B2 (ja) * 2014-08-04 2019-12-25 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ 炎症性、代謝性、腫瘍性および自己免疫疾患の処置に有用なピリミジンの任意選択により縮合されているヘテロシクリル置換誘導体

Also Published As

Publication number Publication date
IL291774A (en) 2022-06-01
US20210188807A1 (en) 2021-06-24
CO2022009510A2 (es) 2022-07-08
PE20230240A1 (es) 2023-02-07
JP2023506357A (ja) 2023-02-16
CL2022001692A1 (es) 2023-03-03
JP2021098691A (ja) 2021-07-01
CA3160508A1 (en) 2021-06-24
MX2022007391A (es) 2022-09-19
JOP20220160A1 (ar) 2023-01-30
JP7106623B2 (ja) 2022-07-26
US20230271937A1 (en) 2023-08-31
CN114728170B (zh) 2024-03-01
AU2020408107A1 (en) 2022-04-14
EP4076661A1 (en) 2022-10-26
WO2021124279A1 (en) 2021-06-24
CR20220355A (es) 2022-09-23
CN114728170A (zh) 2022-07-08
KR20220118425A (ko) 2022-08-25
US11685727B2 (en) 2023-06-27
BR112022012205A2 (pt) 2022-09-13
TW202128661A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
DOP2022000115A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CL2017000240A1 (es) Compuestos activos hacia bromodominios
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
AR088673A1 (es) Formulaciones de peliculas para los dientes
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
CU20200109A7 (es) Derivados de tiadiazina como moduladores del receptor nicotínico de acetilcolina alfa7
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
CO2018005491A2 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CO2021015462A2 (es) Anticuerpos y formulaciones de anti-cd38
CL2021003228A1 (es) Compuestos tricíclicos y su uso
AR107310A1 (es) Inhibidores de tetrahidrocarbazol de receptores sirt1
MX2022012260A (es) Compuestos activos frente a receptores nucleares.
MX2022012259A (es) Compuestos activos frente a receptores nucleares.
AR118756A1 (es) Anticuerpos y formulaciones de anti-cd38